[Market Movement Analysis] Moderna surged on September 17: Positive Phase III results for cancer vaccine and progress in mRNA drugs

1. On August 19, Moderna and Merck announced that the Phase III melanoma trial of the individualized mRNA neoantigen therapy intismeran autogene combined with Keytruda met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. The study enrolled 1,137 patients, and five-year data also showed that the risk of recurrence or death was reduced by 49% compared to Keytruda monotherapy.
2. On September 14, the company disclosed that it is conducting 9 clinical trials with Merck across multiple tumor types, has treated approximately 3,000 patients, and is building automated production facilities. As of June 30, 2026, the company will have 4 approved products and 36 clinical development projects, covering infectious disease vaccines, cancer therapies, and rare disease treatments.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)